Liminatus Pharma
LIMN
10 hedge funds and large institutions have $437K invested in Liminatus Pharma in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.22% more ownership
Funds ownership: 0.79% → 1.01% (+0.22%)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
81% less capital invested
Capital invested by funds: $2.28M → $437K (-$1.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$171K |
| 2 |
Squarepoint
New York
|
+$44.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$39K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.78K |
| 5 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$134 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$32K |
| 2 |
Barclays
London,
United Kingdom
|
-$2.05K |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
-$580 |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$462 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $123K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $106K | -$462 | -107 | -0.2% |
|
|
3
UBS Group
Zurich,
Switzerland
| $67.7K | +$39K | +9,040 | +29% |
|
|
4
Jane Street
New York
| $66.2K | +$171K | +39,635 | New |
|
5
State Street
Boston,
Massachusetts
| $31.7K | – | – | – |
|
6
BlackRock
New York
| $22.1K | – | – | – |
|
|
7
Squarepoint
New York
| $17.4K | +$44.9K | +10,403 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $3.09K | +$5.78K | +1,340 | +264% |
|
9
Bank of America
Charlotte,
North Carolina
| $113 | +$9 | +2 | +3% |
|
|
FFA
10
Farther Finance Advisors
San Francisco,
California
| $52 | +$134 | +31 | New |
|
|
11
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$32K | -2,886 | Closed |
|
|
12
Barclays
London,
United Kingdom
| – | -$2.05K | -184 | Closed |
|
|
SS
13
SBI Securities
Tokyo,
Japan
| – | -$580 | -52 | Closed |
|
LIMN Hedge Fund Activity: Q3 2025 in Review
10 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma (LIMN) for Q3 2025, worth a combined $437K — down 81% from $2.28M a quarter earlier.
Fund positioning in LIMN was balanced in Q3 2025: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $171K. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $32K sold.
- 10 institutional investors held Liminatus Pharma (LIMN) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $437K of Liminatus Pharma stock for Q3 2025, down 81% quarter-over-quarter.
- 3 funds opened new Liminatus Pharma positions in Q3 2025 and 3 closed out, a net change of 0 holders.
- The largest Liminatus Pharma buyer in Q3 2025 was Jane Street, an estimated $171K added.
- The largest Liminatus Pharma seller in Q3 2025 was Royal Bank of Canada, an estimated $32K sold.
Based on aggregated 13F filings for Q3 2025.